Опухолевое микроокружение как мишень терапии злокачественных глиом

Microglial cells in malignant gliomas closely interact with tumor cells. Microenvironment provides local immunosuppression, which promotes escape of tumors from immune system control. Numerous cytokines secreted by microenvironment support survival, nutrition, growth, proliferation and invasion of tumor cells. Microenvironment-targeted therapy is no less important than the traditional cytostatic therapy. Seem promising therapies aimed at reducing the recruitment of immune cells and their amounts in the tumor tissue, at neutralizationof the immunosuppressive properties of microglia and / or inversion of its suppressive phenotype, as well as disinhibition and stimulation of antineoplastic functions of microenvironment.Клетки микроглии в злокачественных глиомах тесным образом взаимодействуют с опухолевыми клетками. Микроокружение обеспечивает локальную иммуносупрессию, которая способствует ускользанию опухоли от иммунного контроля со стороны организма. Многочисленные цитокины, секретируемые микроокружением обеспечивают выживание, питание, рост, пролиферацию и инвазию опухолевых клеток. Лечебное воздействие на микроокружение является не менее значимым, чем традиционная цитостатическая терапия. Перспективными представляются методы терапии, направленные на снижение рекрутинга иммунных клеток и их количества в ткани опухоли, на нейтрализацию иммуносупрессивных свойств микроглии и/или инверсию ее супрессивного фенотипа, а также на растормаживание и стимуляцию тумороцидных функций микроокружения

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptibility loci for different EOC histotypes: six for serous EOC histotypes (3q28, 4q32.3, 8q21.11, 10q24.33, 18q11.2 and 22q12.1), two for mucinous EOC (3q22.3 and 9q31.1) and one for endometrioid EOC (5q12.3). We then performed meta-analysis on the results for high-grade serous ovarian cancer with the results from analysis of 31,448 BRCA1 and BRCA2 mutation carriers, including 3,887 mutation carriers with EOC. This identified three additional susceptibility loci at 2q13, 8q24.1 and 12q24.31. Integrated analyses of genes and regulatory biofeatures at each locus predicted candidate susceptibility genes, including OBFC1, a new candidate susceptibility gene for low-grade and borderline serous EOC